The USFDA has issued seven observations to the Bengaluru facility of Cipla. A routine cGMP inspection was carried out by the USFDA to the API facility of Cipla based at Bengaluru.
The inspection was done between 15 June to 19 June 2019. The company will reply in the stipulated time to the agency.
There is no repeat observation or related with data integrity issued to Cipla's API plant based at Bengaluru.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like